Top Markets
Coin of the day
CytoMed Therapeutics Limited CytoMed Therapeutics Limited

CytoMed Therapeutics Limited

GDTC
株式のランク #32325
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical... CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
株価
$0.88
最終同期: 2026-08-17
時価総額
$10.41M
変化(1日)
-7.26%
変化(1年)
-50.56%
SG
取引 CytoMed Therapeutics Limited (GDTC)

カテゴリー

CytoMed Therapeutics Limited(GDTC)のP/S比率
2026 時点のP/S比率 TTM: 0
CytoMed Therapeutics Limited の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0 です。2026 年末時点でのP/S比率は 0 でした。
CytoMed Therapeutics Limited の P/S 比率の履歴(2026 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/S比率